Epigenetics Diagnostics Market Analysis 2025-2034: Oncology Led with 68.7% Share in 2024, Driven by Demand for Early and Precise Cancer Detection Through Epigenetic Markers
Epigenetics Diagnostics Market
Dublin, June 17, 2025 (GLOBE NEWSWIRE) -- The "Epigenetics Diagnostics Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025-2034" report has been added to ResearchAndMarkets.com's offering.The Global Epigenetics Diagnostics Market was valued at USD 15.5 billion in 2024 and is estimated to grow at a CAGR of 16.5% to reach USD 70.7 billion by 2034. The market is gaining momentum due to the rising awareness of how epigenetic mechanisms contribute to disease development, especially in complex and chronic conditions. The continuous evolution of diagnostic technologies is another key factor driving growth. Increasing cases of chronic illnesses and cancer globally have created a pressing demand for early and accurate detection methods. This, in turn, has fueled the need for advanced epigenetic biomarkers and testing assays.
Additionally, the expanding use of next-generation sequencing technologies and AI-powered analytics has significantly improved the efficiency and scalability of epigenetic diagnostics. The growing preference for non-invasive procedures like liquid biopsies has further encouraged market adoption. Collaborations among pharmaceutical manufacturers, research bodies, and diagnostics firms are increasing to develop safer and more effective diagnostic tools. These initiatives are helping accelerate the transition of epigenetic diagnostics from research labs to mainstream clinical use. With heightened interest in precision medicine, the industry is seeing a sharp focus on the development of highly accurate and scalable solutions that support early intervention and personalized treatment strategies.The market centers on technologies used to detect and analyze epigenetic markers, including DNA methylation and histone modifications, which are pivotal in identifying disease risks and progression. These diagnostics offer valuable insights for early-stage diagnosis and treatment planning across a range of conditions, including cancer and neurological disorders.
Based on product type, the market is segmented into instruments, kits and reagents, and software and services. In 2024, the kits and reagents category led the market with a valuation of USD 7.6 billion. These products are integral to routine diagnostic workflows and are extensively used in clinical settings, academic research, and pharmaceutical development. Their ease of use, reliability, and compatibility with automated and high-throughput systems such as PCR and sequencing platforms make them widely preferred. Continuous improvements in assay sensitivity and integration with advanced technologies are driving further adoption. Additionally, the increasing emphasis on environmentally sustainable and cost-effective reagent development has enhanced accessibility, particularly in developing regions.In terms of application, the epigenetics diagnostics market is split between oncology and non-oncology diagnostics. The oncology diagnostics segment commanded a dominant share of 68.7% in 2024. This growth is propelled by the demand for early and precise cancer detection using epigenetic markers. DNA methylation and histone changes are commonly linked to various forms of cancer and serve as effective indicators for early diagnosis. The rising number of cancer cases, coupled with the shift toward personalized therapies, has heightened interest in epigenetic diagnostics. Awareness campaigns and initiatives promoting early detection and treatment are also playing a pivotal role in expanding this segment.Based on technology, the market includes DNA methylation, histone methylation, microRNA modification, chromatin structure analysis, and other methods. DNA methylation dominated the landscape with a value of USD 6.3 billion in 2024 and is projected to reach USD 28.5 billion by 2034. This segment's strength lies in its capacity to identify disease-specific methylation markers, enabling earlier and more accurate diagnoses. Techniques like bisulfite sequencing, methylation-specific PCR, and array-based assays have advanced the precision of methylation studies, allowing for more effective disease monitoring. Integration of these methods with next-generation sequencing tools continues to improve test sensitivity and throughput, making them increasingly valuable in both research and clinical settings.By end user, the market is divided into hospitals and clinics, pharmaceutical and biotechnology companies, diagnostic laboratories, and others. Hospitals and clinics led the market in 2024 and are expected to reach USD 25.9 billion by 2034. These institutions play a vital role in deploying epigenetic testing for diagnostics, prognosis, and treatment monitoring. Their infrastructure and expertise allow for comprehensive testing and interpretation, including genetic counseling and interdisciplinary collaboration. The trend toward precision medicine has further boosted demand within hospitals, which often serve as central hubs for patient care and advanced diagnostics.Regionally, North America held the largest share in 2024, accounting for 39.7% of the global market. The U.S. alone was valued at USD 5.4 billion in the same year. Factors contributing to the region's dominance include robust healthcare infrastructure, high investments in genomic research, and increased adoption of precision diagnostics. Government initiatives and funding support, especially from research bodies, have helped accelerate innovation in epigenetics. The growing burden of chronic diseases and a strong emphasis on non-invasive diagnostics continue to propel demand in the region.Leading companies - Thermo Fisher Scientific, Illumina, QIAGEN, Agilent Technologies, and Roche Diagnostics - collectively held around 65% of the market share. These firms stay ahead through continuous innovations in sequencing systems, methylation detection tools, and integrated bioinformatics. Their expanding portfolios, including single-cell analysis and targeted panels, align with the rising demand for tailored diagnostic solutions.Comprehensive Market Analysis and Forecast
Industry trends, key growth drivers, challenges, future opportunities, and regulatory landscape
Competitive landscape with Porter's Five Forces and PESTEL analysis
Market size, segmentation, and regional forecasts
In-depth company profiles, business strategies, financial insights, and SWOT analysis
Key Attributes
Report Attribute
Details
No. of Pages
133
Forecast Period
2024-2034
Estimated Market Value (USD) in 2024
$15.5 Billion
Forecasted Market Value (USD) by 2034
$70.7 Billion
Compound Annual Growth Rate
16.5%
Regions Covered
Global
Key Topics CoveredChapter 1 Methodology and Scope1.1 Market scope and definitions1.2 Research design1.2.1 Research approach1.2.2 Data collection methods1.3 Base estimates and calculations1.3.1 Base year calculation1.3.2 Key trends for market estimation1.4 Forecast model1.5 Primary research and validation1.5.1 Primary sources1.5.2 Data mining sourcesChapter 2 Executive Summary2.1 Industry 360 degree synopsisChapter 3 Industry Insights3.1 Industry ecosystem analysis3.2 Industry impact forces3.2.1 Growth drivers3.2.1.1 Increasing prevalence of cancer and chronic diseases3.2.1.2 Advancements in epigenomics research and technology3.2.1.3 Growing demand for non-invasive diagnostics3.2.2 Industry pitfalls and challenges3.2.2.1 High cost of epigenetic diagnostics technologies3.2.2.2 Limited standardization of testing methods3.3 Growth potential analysis3.4 Regulatory landscape3.5 Trump administration tariffs3.5.1 Impact on trade3.5.1.1 Trade volume disruptions3.5.1.2 Retaliatory measures3.5.2 Impact on the Industry3.5.2.1 Supply-side impact (raw materials)3.5.2.1.1 Price volatility in key materials3.5.2.1.2 Supply chain restructuring3.5.2.1.3 Production cost implications3.5.2.2 Demand-side impact (selling price)3.5.2.2.1 Price transmission to end markets3.5.2.2.2 Market share dynamics3.5.2.2.3 Consumer response patterns3.5.3 Key companies impacted3.5.4 Strategic industry responses3.5.4.1 Supply chain reconfiguration3.5.4.2 Pricing and product strategies3.5.4.3 Policy engagement3.5.5 Outlook and future considerations3.6 Technological landscape3.7 Future market trends3.8 Porter's analysis3.9 PESTEL analysisChapter 4 Competitive Landscape, 20244.1 Introduction4.2 Company market share analysis4.3 Company matrix analysis4.4 Competitive analysis of major market players4.5 Competitive positioning matrix4.6 Strategy dashboardChapter 5 Market Estimates and Forecast, by Product, 2021-2034 ($ Mn)5.1 Key trends5.2 Kits and reagents5.3 Instruments5.4 Software and servicesChapter 6 Market Estimates and Forecast, by Application, 2021-2034 ($ Mn)6.1 Key trends6.2 Oncology diagnostics6.3 Non-oncology diagnosticsChapter 7 Market Estimates and Forecast, by Technology, 2021-2034 ($ Mn)7.1 Key trends7.2 DNA methylation7.3 Histone methylation7.4 MicroRNA modification7.5 Chromatin structures7.6 Other technologiesChapter 8 Market Estimates and Forecast, by End Use, 2021-2034 ($ Mn)8.1 Key trends8.2 Hospital and clinics8.3 Pharmaceutical and biotechnology companies8.4 Diagnostic laboratories8.5 Other end useChapter 9 Market Estimates and Forecast, by Region, 2021-2034 ($ Mn)9.1 Key trends9.2 North America9.2.1 U.S.9.2.2 Canada9.3 Europe9.3.1 Germany9.3.2 UK9.3.3 France9.3.4 Spain9.3.5 Italy9.3.6 Netherlands9.4 Asia-Pacific9.4.1 China9.4.2 Japan9.4.3 India9.4.4 Australia9.4.5 South Korea9.5 Latin America9.5.1 Brazil9.5.2 Mexico9.5.3 Argentina9.6 Middle East and Africa9.6.1 South Africa9.6.2 Saudi Arabia9.6.3 UAEChapter 10 Company Profiles10.1 Abcam10.2 Agilent Technologies10.3 Diagenode10.4 Dovetail Genomics10.5 Element Biosciences10.6 Illumina10.7 Merck10.8 New England Biolabs10.9 PacBio10.10 Promega10.11 QIAGEN10.12 Roche Diagnostics10.13 Thermo Fisher Scientific10.14 Zymo Research
For more information about this report visit https://www.researchandmarkets.com/r/akxx7j
About ResearchAndMarkets.comResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Attachment
Epigenetics Diagnostics Market
CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood,Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
a few seconds ago
- Yahoo
I sold $3K in gold via wire transfer, but then the buyer got their bank to reverse the payment. What can I do?
Buyer-beware scams are in the headlines every day, but a growing number of buyers are ripping off businesses by reversing charges on their purchases. This is a seller-beware scenario. Imagine you run a precious metals store and a customer wants to buy $3,000 worth of gold via wire transfer. You verify their identity, complete the sale and hand over the gold. All by the book, right? Don't miss Thanks to Jeff Bezos, you can now become a landlord for as little as $100 — and no, you don't have to deal with tenants or fix freezers. Here's how I'm 49 years old and have nothing saved for retirement — what should I do? Don't panic. Here are 6 of the easiest ways you can catch up (and fast) Want an extra $1,300,000 when you retire? Dave Ramsey says this 7-step plan 'works every single time' to kill debt, get rich in America — and that 'anyone' can do it Not quite. A month later, the customer calls their bank to dispute the charge, claiming they were tricked into buying the gold by a third party. The bank is convinced by the customer's story, cancels the wire transfer and withdraws money from your merchant account, leaving you without payment — and your store down $3,000 worth of gold, which is hard to trace. The same thing can happen with customers who request the reversal of electronic fund transfers (EFTs) or credit card charges. Such transactions are called 'friendly fraud" or "chargeback fraud." The customer may indeed have been the victim of a scam, or be pulling off a scam themselves. Either way, your business is left with a loss. Unfortunately, it's not an uncommon occurrence, particularly for businesses dealing in precious gems and metals, which are frequently targeted in scams. Here's what happens and how to protect your business. Banks often side with customers in cases of alleged fraud Banks typically allow chargebacks or payment reversals only under certain conditions: Unauthorized transactions. The customer claims they didn't authorize the purchase. Billing errors. The charge was duplicated, incorrect, or charged in the wrong amount. Fraudulent activity. The purchase was made under false pretenses or through deception. Failure to receive goods or services. The item was never delivered, was defective, or didn't match the description. In many cases, banks default to protecting the consumer, especially when fraud is alleged. However, with wire transfers, often considered final and irreversible, the rules are more complicated and the reversal takes more time. Read more: Nervous about the stock market? Gain potential quarterly income through this $1B private real estate fund — even if you're not a millionaire. Some banks will allow customers to file a complaint and launch an investigation, especially if they claim they were defrauded or coerced into making a purchase. If the bank believes the customer acted in good faith, it may choose to reverse the charge, even if the merchant did nothing wrong. That's what makes this type of situation so frustrating for business owners. What to do if your business falls victim to this scam Once a bank reverses a wire transfer, it's tough to undo. So be proactive. If a bank contacts your business about potential fraud, respond promptly. Providing proof, such as receipts, can help your case before the funds are reversed. After funds are reversed, you still have a few options: Dispute the reversal. Provide documentation showing the customer authorized the purchase and received the goods. This could include signed receipts, invoices, tracking data, or even video footage. File a police report. If the customer's story involves criminal fraud, getting law enforcement involved may help clarify who's actually at fault. Seek legal action. If the bank won't reverse its decision, the business may consider small claims court or civil litigation to recover the funds. Consult with the bank. Each bank has its own internal process. Sometimes, escalating the issue to a higher level of review can change the outcome. To avoid issues in the future, consider implementing more advanced due diligence processes for high-dollar sales — especially for gems and precious metals, which are frequently targeted in scams. You can leverage technology in your business's fight against friendly fraud. A number of companies offer AI-based fraud prevention software, including Signifyd — designed to protect online retailers — and Arctic Intelligence. Arctic Intelligence advises training staff to identify questionable purchases. They should ask for proof of the source of funds for any big transaction, particularly with a new client, and report suspected money laundering to law enforcement. What to read next Robert Kiyosaki warns of a 'Greater Depression' coming to the US — with millions of Americans going poor. But he says these 2 'easy-money' assets will bring in 'great wealth'. How to get in now Here are 5 simple ways to grow rich with real estate if you don't want to play landlord. And you can even start with as little as $10 Rich, young Americans are ditching the stormy stock market — here are the alternative assets they're banking on instead Here are 5 'must have' items that Americans (almost) always overpay for — and very quickly regret. How many are hurting you? Stay in the know. Join 200,000+ readers and get the best of Moneywise sent straight to your inbox every week for free. This article provides information only and should not be construed as advice. It is provided without warranty of any kind. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
a few seconds ago
- Yahoo
Intel in talks with large investors for equity boost at discount, CNBC reports
(Reuters) -Intel is in talks with other large investors to receive an equity infusion at a discounted price, CNBC reported on Wednesday, just days after the chipmaker got a $2 billion capital injection from SoftBank Group. This also follows Reuters report U.S. Commerce Secretary Howard Lutnick is looking into the government taking equity stakes in Intel and other chipmakers in exchange for grants under the CHIPS Act, which aims to spur factory-building in the U.S. Intel did not immediately respond to a Reuters request for comment. Silicon Valley pioneer Intel has been struggling from years of missteps in its manufacturing operation and missed opportunities around the artificial intelligence boom, culminating into one of the most difficult periods in the company's history. The company lost its competitive edge years ago to Taiwan Semiconductor Manufacturing Co, the globe's biggest contract manufacturer. Chip designer Nvidia is dominating in the AI chips market, while Intel is losing market share in PCs and datacenters to rival Advanced Micro Devices.
Yahoo
a few seconds ago
- Yahoo
Trump expands 50% tariff on steel and aluminum to 400 additional product types
The Department of Commerce announced that President Donald Trump's 50% tariff on imported steel and aluminum products has been expanded to cover more than 400 additional categories. The expanded tariff list, published Friday by U.S. Customs and Border Protection and entered into the Federal Register on Tuesday, took effect Monday. The new duties now apply to a wide range of goods, including auto parts, electric vehicle components, railcars, marine engines, construction equipment, wind turbines, cranes, chemicals, plastics, and household items such as refrigerators, freezers, dryers, and furniture components. 'Today's action expands the reach of the steel and aluminum tariffs and shuts down avenues for circumvention — supporting the continued revitalization of the American steel and aluminum industries,' Jeffrey Kessler, Commerce Department Secretary for Industry and Security, said in a news release. The move follows petitions from U.S. steelmakers, including Cleveland-Cliffs and Nucor, urging the administration to broaden import duties to cover more derivative products. Industry experts said the expansion marks a significant shift in how steel and aluminum imports are regulated. 'Auto parts, chemicals, plastics, furniture components — basically, if it's shiny, metallic, or remotely related to steel or aluminum, it's probably on the list,' Brian Baldwin, vice president of customs at Kuehne + Nagel International AG, wrote on LinkedIn. In 2024, the U.S. imported nearly $33 billion worth of steel and aluminum, according to SteelRadar. Canada remains the largest supplier, followed by Brazil and Mexico. The Mexican Institute for Competitiveness (IMCO) estimates the tariffs will affect 4.7% of Mexican exports to the U.S. 'Aluminum and steel are vital for the manufacture of products ranging from utensils to airplanes and railroad equipment,' IMCO researcher Isaac Cruz wrote earlier this year. 'U.S. manufacturers benefit from competitive prices that would be lost if tariffs were implemented; the same is true for American consumers and families.' Mexico has requested an exemption from the new tariffs. 'We're discussing the application of tariffs on steel products because they're stretching the boundaries and adding more things, and that could hurt us,' Marcelo Ebrard, Mexico's economy secretary, said on Saturday, according to Opportimes. 'But, at the end of the day, what do we want to achieve? A position (on tariffs) for Mexico that's better than any other country.' The post Trump expands 50% tariff on steel and aluminum to 400 additional product types appeared first on FreightWaves. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
